IP Library Granted Patent US 7,070,993
Granted Patent B2
US 7,070,993 · App. 10/097,002 · Granted Jul 4, 2006

Lentiviral packaging constructs

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,070,993
App. No.
10/097,002
Granted
Jul 4, 2006
Kind
B2
Abstract

The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.

Claims (24)

1. A lentiviral packaging construct for use in generating lentiviral vectors comprising a sequence encoding a lentiviral protease gene and a deletion in a lentiviral packaging signal sequence, wherein said sequence encoding said protease includes a substitution wherein the T in the DTGAD (residues 25–29 of SEQ ID NO:1) motif is replaced with an S.

2. The construct of claim 1 , wherein said sequence encoding said protease comprises a lentiviral pol gene.

3. The packaging construct of claim 1 wherein said lentiviral protease is an HIV protease.

4. The packaging construct of claim 1 wherein said lentiviral protease is a BIV protease.

5. The packaging construct of claim 1 wherein said lentiviral protease is an EIAV protease.

6. The packaging construct of claim 1 wherein said lentiviral protease is an SIV protease.

7. The packaging construct of claim 1 wherein said lentiviral protease is an FIV protease.

8. The construct of claim 2 , further comprising a lentiviral gag gene.

9. The packaging construct of claim 1 , 2 or 8 which is obtained from an HIV genome.

10. The packaging construct of claim 1 , 2 or 8 which is obtained from a BIV genome.

11. A pre-packaging cell line comprising said packaging construct of claim 1 , 2 or 8 .

12. The packaging construct of claim 9 further comprising a deletion of, or mutation in, a vif gene, a vpr gene or both.

13. The packaging construct of claim 10 further comprising a deletion of, or mutation in, one or more of a vif gene, a W gene, a Y gene or a Tat gene.

14. The pre-packaging cell line of claim 2 or 8 wherein expression of the lentiviral pol gene is constitutive.

15. The pre-packaging cell line of claim 8 wherein expression of the lentiviral gag gene is constitutive.

16. The pre-packaging cell line of claim 11 wherein expression of the lentiviral protease gene is constitutive.

17. A packaging cell line comprising the pre-packaging cell line of claim 11 and further comprising an env gene.

18. A packaging cell line comprising the prepackaging cell line of claim 16 and further comprising an env gene.

19. A packaging cell line comprising the prepackaging cell line of claim 14 and further comprising an env gene.

20. A packaging cell line comprising the prepackaging cell line of claim 15 and further comprising an env gene.

21. A producer cell line comprising the packaging cell line of claim 17 and further comprising a lentiviral vector.

22. A producer cell line comprising the packaging cell line of claim 18 and further comprising a lentiviral vector.

23. A producer cell line comprising the packaging cell line of claim 19 and further comprising a lentiviral vector.

24. A producer cell line comprising the packaging cell line of claim 20 and further comprising a lentiviral vector.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2002
From: KALEKO, MICHAEL; LUO, TIANCI; PLAVEC, IVAN; DOUGLAS, JANET LYNN
To: NOVARTIS AG
Reel/Frame 013047/0907 →
Continuity (2)
Provisional Application 6027527500 · Mar 13, 2001
Related Publication 20030054548A1 · Mar 20, 2003